The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Jun 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called N-acetylcysteine (NAC) can help prevent blood clots, known as thrombotic events, in patients who are about to receive a special type of treatment called allogenic hematopoietic stem cell transplantation (allo-HSCT). This treatment is often used for people with certain blood cancers. The study will check both the effectiveness and safety of NAC in this setting.

To participate in the trial, you need to be between 16 and 70 years old and diagnosed with myeloid malignancies (a type of blood cancer). You should also be healthy enough to have this procedure and expected to live for at least a month afterward. However, if you have allergies to NAC or severe problems with your heart, liver, lungs, or kidneys, or if you have had a relapse of your illness before the transplant, you won’t be able to join. The trial is not yet recruiting participants, but it aims to contribute valuable information about improving care for patients undergoing this treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 16-70 years old
• • 2. Diagnosed as myeloid malignancies, and about to undergo allo-HSCT;
• • 3. ECOG: 0-2;
• • 4. Expected survival longer than 1 month
• Exclusion Criteria:
• • 1. Allergic to any components of NAC;
• • 2. Severe dysfunction of heart, liver, lung and kidney;
• • 3. Relapse before HSCT;
• • 4. A history of bronchial asthma, bronchospasm or moderate / severe gastrohelcosis.